Payment overview · 2025
General Payments
$380.94
21 reported records · 12 companies
Healthcare provider profile · identity verified
Ashley Berkley, DO
Allopathic & Osteopathic Physicians|Family Medicine · MEYERSDALE, PA · NPI 1437395290
Verified facts
What the public records show
CMS Open Payments records show Ashley Berkley, DO received $380.94 in general payments during 2025 across 21 reported records.
ABBVIE INC. accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.43 | 15.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.39 | 13.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.42 | 12.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.93 | 10.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.08 | 9.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.73 | 8.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $26.65 | 7.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.61 | 5.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.13 | 4.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.37 | 4.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.13 | 4.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.07 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $380.94 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $44.81 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.39 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.39 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.25 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 347 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
347 | 58 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
347 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1100 | 221 |
| Pantoprazole Sodium | Pantoprazole Sodium | 861 | 177 |
| Amlodipine Besylate | Amlodipine Besylate | 740 | 169 |
| Lisinopril | Lisinopril | 662 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 629 | 110 |
| Furosemide | Furosemide | 490 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 103 |
| Losartan Potassium | Losartan Potassium | 380 | 72 |
| Gabapentin | Gabapentin | 374 | 71 |
| Omeprazole | Omeprazole | 350 | 80 |
| Eliquis | Apixaban | 347 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 344 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 325 | 64 |
| Potassium Chloride | Potassium Chloride | 311 | 74 |
| Carvedilol | Carvedilol | 305 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 81 |
| Lorazepam | Lorazepam | 298 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 61 |
| Metformin Hcl | Metformin Hcl | 264 | 57 |
| Alprazolam | Alprazolam | 254 | 44 |
| Sertraline Hcl | Sertraline Hcl | 250 | 47 |
| Allopurinol | Allopurinol | 226 | 46 |
| Mounjaro | Tirzepatide | 219 | 33 |
| Spironolactone | Spironolactone | 212 | 41 |
| Jardiance | Empagliflozin | 209 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 205 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 198 | 47 |
| Simvastatin | Simvastatin | 181 | 29 |
| Metformin Hcl Er | Metformin Hcl | 176 | 47 |
| Prednisone | Prednisone | 176 | 110 |
| Ropinirole Hcl | Ropinirole Hcl | 171 | 27 |
| Bupropion Xl | Bupropion Hcl | 168 | 31 |
| Trazodone Hcl | Trazodone Hcl | 168 | 38 |
| Trulicity | Dulaglutide | 167 | 35 |
| Celecoxib | Celecoxib | 159 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 54 |
| Valsartan | Valsartan | 148 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 146 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 138 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 53 |
| Atenolol | Atenolol | 134 | 25 |
| Donepezil Hcl | Donepezil Hcl | 124 | 24 |
| Meloxicam | Meloxicam | 121 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 23 |
| Synthroid | Levothyroxine Sodium | 118 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 117 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 110 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 109 | 16 |
| Unifine Pentips | Pen Needle, Diabetic | 107 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 30 |
| Alendronate Sodium | Alendronate Sodium | 103 | 23 |
| Warfarin Sodium | Warfarin Sodium | 98 | 18 |
| Montelukast Sodium | Montelukast Sodium | 97 | 25 |
| Tramadol Hcl | Tramadol Hcl | 92 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 22 |
| Cephalexin | Cephalexin | 80 | 68 |
| Buspirone Hcl | Buspirone Hcl | 78 | 12 |
| Bumetanide | Bumetanide | 77 | 19 |
| Glimepiride | Glimepiride | 76 | 16 |
| Ozempic | Semaglutide | 74 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 33 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 72 | 13 |
| Dutasteride | Dutasteride | 70 | 15 |
| Xarelto | Rivaroxaban | 70 | 11 |
| Memantine Hcl | Memantine Hcl | 69 | 12 |
| Myrbetriq | Mirabegron | 68 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 14 |
| Pregabalin | Pregabalin | 64 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 14 |
| Famotidine | Famotidine | 60 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 14 |
| Finasteride | Finasteride | 59 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 53 |
| Colchicine | Colchicine | 55 | suppressed |
| Glipizide Er | Glipizide | 53 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 50 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 16 |
| Primidone | Primidone | 46 | suppressed |
| Azithromycin | Azithromycin | 44 | 44 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 43 | 11 |
| Glipizide | Glipizide | 43 | suppressed |
| Tradjenta | Linagliptin | 43 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Digoxin | Digoxin | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | 15 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 39 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 25 |
| Torsemide | Torsemide | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Linzess | Linaclotide | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 27 | suppressed |
| Febuxostat | Febuxostat | 27 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 27 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 13 |
| Sucralfate | Sucralfate | 24 | 15 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Nyamyc | Nystatin | 21 | suppressed |
| Nystatin | Nystatin | 21 | 19 |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Insulin Aspart | Insulin Aspart | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $380.94 · 21 records | ABBVIE INC. | ABRYSVO, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, IBSRELA, MINIMED 780G, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, RINVOQ, The Cologuard Plus Collection Kit, VRAYLAR, VYEPTI, XIFAXAN, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error